ArticleESMO open2021
Breast cancer in very young women-a multicenter 10-year experience.
Article in ESMO open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer.The oncologist · 2024Trial
- Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.Journal of the National Cancer Institute · 2022Trial
- Breast Cancer in Women Aged ≤35 Years: A Single-Center Retrospective Comparative Analysis by Age Subgroup.Diagnostics (Basel, Switzerland) · 2026Article
- Very young age stratification and development of a multiple-imputation Cox nomogram for disease-free survival in breast cancer women aged ≤40 years.The oncologist · 2026Article
- Prognosis of Breast Cancer in Women in Their 20s: Clinical and Radiological Insights.Diagnostics (Basel, Switzerland) · 2025Article
- Genetic counseling referral rates and genetic testing outcomes in women with young breast cancer: a 20-year Canadian review.Breast cancer research and treatment · 2025Article
- Article
- Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study.Medicina (Kaunas, Lithuania) · 2025Article
- Exosomal Delivery of miR-155 Inhibitor can Suppress Migration, Invasion, and AngiogenesisCurrent medicinal chemistry · 2025Article
- Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer among young women (≤35): a retrospective cohort study based on SEER database and TJMUCH registry.American journal of cancer research · 2025Article
- Age and Late Recurrence in Young Patients With ER-Positive, ERBB2-Negative Breast Cancer.JAMA network open · 2024Article
- Tumour biology and survival outcomes in young women with breast cancer: single-centre retrospective analysis.BJS open · 2024Article
- Young Women with Early-Stage Breast Cancer Treated with Upfront Surgery: Overview of Oncological Outcomes.Journal of clinical medicine · 2024Article
- A nomogram for predicting overall survival of breast cancer with regional lymph node metastasis in young women.Translational cancer research · 2024Article
- Long-term oncologic outcomes following breast cancer surgery in adolescents and young adults: a single-center retrospective analysis.Frontiers in oncology · 2024Article
- Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study.Breast cancer research and treatment · 2024Article
- Article
- A deep-learning-based clinical risk stratification for overall survival in adolescent and young adult women with breast cancer.Journal of cancer research and clinical oncology · 2023Article
- Clinical features and prognostic factors of breast cancer in young women: a retrospective single-center study.Archives of gynecology and obstetrics · 2023Article
- Establishment and Verification of Prognostic Nomograms for Young Women With Breast Cancer Bone Metastasis.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is the most prevalent cancer in adult young women in Europe. Although rare, it is one of the leading causes of death in this age group. The aim of this study is to characterize a cohort of young women regarding tumor stage, biology, treatment and survival. PATIENTS AND
methodsWe present a multicenter retrospective analysis of women <35 years of age, diagnosed with BC between 2008 and 2017. A total of 207 patients from five Portuguese centers were included, from whom 172 were eligible for analysis. Data were analyzed using IBM SPPSS statistics.
resultsMedian age at diagnosis was 31 years. Fifty-one percent of tumors were hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative, 20% HR-positive/HER2-positive, 8% HR-negative/HER2-positive and 20% triple-negative BC. Twenty-two percent of patients were diagnosed in stage I, 26% stage II, 45% stage III and 6% had de novo metastatic cancer. Thirty-nine percent of patients were treated with neoadjuvant chemotherapy. Mean follow-up time was 64.9 months and overall survival at 5 years, of the entire cohort and metastatic patients, was 86.5% and 26%, respectively.
conclusionsIn our study we found similar population characteristics to other cohorts <35 years of age. To our knowledge, this is one of the largest cohorts in very young women. BC in young women is an important issue and further studies are needed to provide better care and survivorship to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.